Pulmonary toxicities of tyrosine kinase inhibitors

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) are crucial in cancer therapy.
• Pulmonary toxicities are a known, albeit infrequent, adverse event associated with TKIs.
• Reported incidence of TKI-induced pulmonary toxicity varies widely (0.2%–10.9%).

Purpose of the Study:

• To review and identify rare but fatal pulmonary toxicities caused by specific TKIs.
• To consolidate data on interstitial lung disease (ILD) as a primary manifestation of TKI-induced lung injury.

Main Methods:

• Literature review of case reports and studies on TKI-related pulmonary toxicities.
• Focus on TKIs such as gefitinib, erlotinib, and imatinib.
• Analysis of reported incidence and outcomes of pulmonary adverse events.

Main Results:

• Pulmonary toxicities, predominantly interstitial lung disease, are very rare adverse events.
• Gefitinib and erlotinib (EGFR inhibitors) and imatinib (BCR-ABL inhibitor) are associated with these toxicities.
• While rare, these events can be fatal, highlighting the need for vigilance.

Conclusions:

• Pulmonary toxicity is a rare but potentially fatal complication of TKI therapy.
• Interstitial lung disease is the most common severe pulmonary manifestation.
• Awareness and monitoring are essential for patients receiving TKIs.